Healthcare entity
Every one of those 2 sits in a single category, market-trends. Of the tracked stories, 1 of 2 also mention Armanino Foods of Distinction, Inc., the most common co-covered peer. Source depth averages 2 original sources per story, versus 3 across the same-window beat baseline.
Last mentioned: Mar 19, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 2 sits in a single category, market-trends. Of the tracked stories, 1 of 2 also mention Armanino Foods of Distinction, Inc., the most common co-covered peer. Source depth averages 2 original sources per story, versus 3 across the same-window beat baseline. At 5, the average consequence score sits below the same-window beat average of 5.9. We currently track 2 Healthcare stories that mention Ameluz, all published on March 19, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 30 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Ameluz. Shared-story counts are live from our verified record — not editorial picks.
Q4 2025 Earnings
Both companies report year-end results showing strong commercial momentum and narrowing losses.
Major Health Plan Contract
DarioHealth signs a multi-year agreement with a top-five national US health insurer.
Biofrontera Supply Chain Update
Resolution of RhodoLED manufacturing bottlenecks, enabling faster lamp deployment.
DarioHealth MSK Launch
Full integration of musculoskeletal health modules into the core digital platform.
Biofrontera and DarioHealth reported Q4 2025 earnings, highlighting a pivotal transition from clinical development to aggressive commercial scaling. While Biofrontera capitalizes on its dermatology market share with Ameluz, DarioHealth is demonstrating the viability of its multi-condition digital health platform through expanded B2B partnerships.
Source: finance.yahoo.com · finance.yahoo.com
Biofrontera Inc. (Nasdaq: BFRI) has reported record-breaking financial results for the fourth quarter and full year 2025, signaling a major milestone in the commercial adoption of its photodynamic therapy (PDT) solutions. The company is leveraging increased market penetration of its flagship product, Ameluz, and its proprietary BF-RhodoLED lamps across U.S. dermatology practices.
Source: finanznachrichten.de · manilatimes.net
Ameluz is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
